Automated CD34+ cell isolation of peripheral blood stem cell apheresis product

  • Gabriele Spohn
  • , Eliza Wiercinska
  • , Darja Karpova
  • , Milica Bunos
  • , Christiane Hümmer
  • , Eva Wingenfeld
  • , Nadine Sorg
  • , Carolin Poppe
  • , Volker Huppert
  • , Juliane Stuth
  • , Kristina Reck
  • , Mike Essl
  • , Erhard Seifried
  • , Halvard Bönig

Research output: Contribution to journalArticlepeer-review

Abstract

Background aims: Immunomagnetic enrichment of CD34+ hematopoietic "stem" cells (HSCs) using paramagnetic nanobead coupled CD34 antibody and immunomagnetic extraction with the CliniMACS plus system is the standard approach to generating T-cell-depleted stem cell grafts. Their clinical beneficence in selected indications is established. Even though CD34+ selected grafts are typically given in the context of a severely immunosuppressive conditioning with anti-thymocyte globulin or similar, the degree of T-cell depletion appears to affect clinical outcomes and thus in addition to CD34 cell recovery, the degree of T-cell depletion critically describes process quality. An automatic immunomagnetic cell processing system, CliniMACS Prodigy, including a protocol for fully automatic CD34+ cell selection from apheresis products, was recently developed. We performed a formal process validation to support submission of the protocol for CE release, a prerequisite for clinical use of Prodigy CD34+ products. Methods: Granulocyte-colony stimulating factor-mobilized healthy-donor apheresis products were subjected to CD34+ cell selection using Prodigy with clinical reagents and consumables and advanced beta versions of the CD34 selection software. Target and non-target cells were enumerated using sensitive flow cytometry platforms. Results: Nine successful clinical-scale CD34+ cell selections were performed. Beyond setup, no operator intervention was required. Prodigy recovered 74 ± 13% of target cells with a viability of 99.9 ± 0.05%. Per 5 × 10E6 CD34+ cells, which we consider a per-kilogram dose of HSCs, products contained 17 ± 3 × 10E3 T cells and 78 ± 22 × 10E3 B cells. Conclusions: The process for CD34 selection with Prodigy is robust and labor-saving but not time-saving. Compared with clinical CD34+ selected products concurrently generated with the predecessor technology, product properties, importantly including CD34+ cell recovery and T-cell contents, were not significantly different. The automatic system is suitable for routine clinical application.

Original languageEnglish
Pages (from-to)1465-1471
Number of pages7
JournalCytotherapy
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2015

Keywords

  • Allogeneic
  • Automation
  • CD34
  • Cell therapy
  • Clean room
  • CliniMACS
  • Good manufacturing practice
  • Haplo-identical
  • Immunomagnetic
  • Naked haplo
  • Prodigy
  • Stem cell transplantation

Fingerprint

Dive into the research topics of 'Automated CD34+ cell isolation of peripheral blood stem cell apheresis product'. Together they form a unique fingerprint.

Cite this